Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/09/26
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/09/26
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking CessationGlobeNewsWire • 08/31/26
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 08/29/26
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to RunThe Motley Fool • 08/23/26
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y RevenuesZacks Investment Research • 08/11/26
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value PropositionSeeking Alpha • 08/11/26
Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/10/26
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/26
Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key MetricsZacks Investment Research • 08/05/26
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 08/03/26
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in NarcolepsyGlobeNewsWire • 07/15/26
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10GlobeNewsWire • 07/14/26